In conclusion, both serum or plasma IL-23 levels have been shown to be associated with autoimmune disease pathogenesis and may provide a clinical basis for early detection, early treatment, and dynamic assessment of patient outcomes in AD patients. This evidence concerns the gene IL23A and autoimmune disease.